Active substances: Orlistat
Insulin resistance not only affects glucose metabolism; increased free fatty acids and triglycerides are hallmarks of insulin resistance. The obese woman begins pregnancy with greater insulin resistance than her normal weight counterpart.
This progressively increases as the pregnancy progresses. If the beta cell cannot compensate for the increase in insulin resistance, glucose levels rise.
The developing fetoplacental unit is exposed to these metabolic changes.However, there is little evidence that lifestyle modification alters pregnancy outcomes pregnancy suggest lifestyle modification before conception.
Similarly, a small decrease in maternal glucose is associated with a lower risk of adverse pregnancy outcomes. For example, a reduction in maternal fasting glucose from glucose category 5 5.
However, the combination has a greater impact than either one alone. The same association exists if pre-pregnancy BMI based on patient recall is considered.
Weight loss improves glycemic control. Pre-pregnancy weight reduction has the potential to improve pregnancy outcomes, directly through weight loss and indirectly through improved glycemic control.
Regardless of the method of weight loss, the counter-regulatory responses to weight loss will result in a tendency to weight regain.
Importantly, the rate of weight regain is not altered by the rate of weight loss.
This would allow a window for conception at a time of lower weight. In considering weight loss in an obese woman before pregnancy, we must identify a weight loss target that both increases fertility and decreases the risks of adverse pregnancy outcomes due to obesity.
This study aims to address this need by exploring the impact of substantial pre-conception weight loss in obese woman on maternal and fetal pregnancy outcomes.
A reduction in the rate of LGA infants.
A reduction in the rate of IUGR. A reduction in the rate of primary Cesarean section. A reduction in the rate of neonatal hypoglycemia. A reduction in the rate of neonatal hyperbilirubinemia.
A reduction in that rate of neonatal special care nursery or intensive care admission. A reduction in maternal and neonatal length of stay.
A decrease in the time to conception. An increase in live birth rate.
No difference in maternal gestational weight gain. Xenical contains the active ingredient Orlistat. Orlistat is also the name of the less expensive brand of Xenical.
Both medications are medically equivalent.